^
My recent searches
No previous search
PD-L1 expression
NSCLC
Sensitive: A1 - Approval
AstraZeneca Press Release - 1 day
No biomarker
Urothelial Cancer
Sensitive: B - Late Trials
Cision - 1 day
ALK positive
NHL
Sensitive: A1 - Approval
FDA - 2 days
No biomarker
CLL
Sensitive: A1 - Approval
Cision - 3 days
No biomarker
NSCLC
Sensitive: A1 - Approval
BeiGene Press Release - 3 days
No biomarker
Sarcoma
Sensitive: B - Late Trials
Inhibrx Press Release - 3 days
EGFR exon 19 deletion
NSCLC
Sensitive: A1 - Approval
J Cancer Res Clin Oncol - 4 days
HER-2 positive
HER2 Positive Breast Cancer
Sensitive: A1 - Approval
J Oncol Pharm Pract - 4 days
No biomarker
AML
Sensitive: A1 - Approval
Cision - 4 days
TMB-H
NSCLC
Sensitive: A2 - Guideline
IASLC-WCLC 2020 - 4 days
EGFR L858R
NSCLC
Sensitive: B - Late Trials
IASLC-WCLC 2021 - 4 days
EGFR exon 19 deletion
NSCLC
Sensitive: B - Late Trials
IASLC-WCLC 2021 - 4 days
EGFR mutation
Lung Cancer
Sensitive: B - Late Trials
IASLC-WCLC 2020 - 4 days
MLL3 mutation + TMB-H
NSCLC
Sensitive: B - Late Trials
IASLC-WCLC 2020 - 4 days
MLL3 mutation + TMB-H
NSCLC
Sensitive: B - Late Trials
IASLC-WCLC 2020 - 4 days
RET fusion
Lung Cancer
Sensitive: B - Late Trials
IASLC-WCLC 2021 - 4 days
KMT2D mutation + TMB-H
NSCLC
Sensitive: B - Late Trials
IASLC-WCLC 2020 - 4 days
KRAS G12C
Lung Non-Squamous Non-Small Cell Cancer
Sensitive: B - Late Trials
IASLC-WCLC 2020 - 4 days
KMT2D mutation + TMB-H
NSCLC
Sensitive: B - Late Trials
IASLC-WCLC 2020 - 4 days
BRAF V600E
GBM
Sensitive: C1 - Off-label
Curr Probl Cancer - 4 days
EGFR T790M
NSCLC
Sensitive: C2 – Inclusion Criteria
Cancer - 4 days
TMB-H + PD-L1 overexpression
NSCLC
Sensitive: C3 – Early Trials
IASLC-WCLC 2021 - 4 days
TNB-H
NSCLC
Sensitive: C3 – Early Trials
IASLC-WCLC 2021 - 4 days
PD-L1 overexpression
Peripheral T-cell Lymphoma
Sensitive: C3 – Early Trials
J Hematol Oncol - 4 days
ALK rearrangement
LUAD
Sensitive: C3 – Early Trials
IASLC-WCLC 2020 - 4 days
HER-2 amplification
NSCLC
Sensitive: C3 – Early Trials
IASLC-WCLC 2021 - 4 days
STK11 mutation
NSCLC
Sensitive: C3 – Early Trials
IASLC-WCLC 2021 - 4 days
HER-2 G766V
NSCLC
Sensitive: C3 – Early Trials
IASLC-WCLC 2021 - 4 days
EGFR mutation
LUAD
Sensitive: C3 – Early Trials
IASLC-WCLC 2020 - 4 days
EGFR mutation + KRAS mutation
Lung Non-Squamous Non-Small Cell Cancer
Sensitive: C3 – Early Trials
IASLC-WCLC 2020 - 4 days
HER-2 A775_G776insYVMA
NSCLC
Sensitive: C3 – Early Trials
IASLC-WCLC 2021 - 4 days
PRDX1 exon 5 - NTRK1 exon 12 fusion
LUAD
Sensitive: C4 – Case Studies
IASLC-WCLC 2020 - 4 days
EGFR exon 20 insertion
NSCLC
Resistant: C3 – Early Trials
IASLC-WCLC 2021 - 4 days
EGFR overexpression
Osteosarcoma
Resistant: D – Preclinical
Acta Biochim Biophys Sin (Shanghai) - 4 days
No biomarker
Urothelial Cancer
Sensitive: A1 - Approval
Cision - 5 days
MSI-H/dMMR
CRC
Sensitive: A1 - Approval
ASCO-GI 2021 - 5 days
MSI-H/dMMR
CRC
Sensitive: A1 - Approval
ASCO-GI 2021 - 5 days
RET fusion
Thyroid Gland Carcinoma
Sensitive: A1 - Approval
ASCO-GI 2021 - 5 days
BRCA2 mutation
Pancreatic Cancer
Sensitive: A1 - Approval
ASCO-GI 2021 - 5 days
BRCA1 mutation
Pancreatic Cancer
Sensitive: A1 - Approval
ASCO-GI 2021 - 5 days
IDH1 mutation
Cholangiocarcinoma
Sensitive: A2 - Guideline
ASCO-GI 2021 - 5 days
HER-2 amplification
CRC
Sensitive: A2 - Guideline
ASCO-GI 2021 - 5 days
EGFR mutation
LUAD
Sensitive: B - Late Trials
BMC Cancer - 5 days
BRAF mutation
CRC
Sensitive: B - Late Trials
ASCO-GI 2021 - 5 days
BRAF mutation
CRC
Sensitive: B - Late Trials
ASCO-GI 2021 - 5 days
No biomarker
Merkel Cell Carcinoma
Sensitive: B - Late Trials
Exicure Press Release - 5 days
EGFR mutation
LUAD
Sensitive: C1 - Off-label
BMC Cancer - 5 days
RET fusion
Pancreatic Cancer
Sensitive: C1 - Off-label
ASCO-GI 2021 - 5 days
RET fusion
Cholangiocarcinoma
Sensitive: C1 - Off-label
ASCO-GI 2021 - 5 days
HER-2 overexpression
Gastric Cancer
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2021 - 5 days